ISSN: 2576-1447
+44 1478 350008
Cecile Rose T Vibat
United States
Case Report
Clinical Utility of Target Selectorâ„¢ ctDNA Testing: Detection of EGFR Mutations via Liquid Biopsy Enabled Targeted Therapy Selection for Patients with Advanced NSCLC
Author(s): Veena M Singh, Rodrigo Erlich and Cecile Rose T VibatVeena M Singh, Rodrigo Erlich and Cecile Rose T Vibat
Background: Molecular profiling of tumors provides information key for devising personalized therapeutic strategies for managing disease in cancer patients. A liquid biopsy is emerging as a sensitive means to evaluate biomarker status without the complications and costs associated with surgical biopsies, particularly for patients unable or unwilling to undergo invasive procedures.
Materials and Methods: Patient blood specimens were collected in Biocept’s proprietary Blood Collection Tubes for liquid biopsy testing in Biocept’s CLIA-certified, CAP-accredited laboratory. Dual Circulating Tumor Cell (CTC) and circulating tumor DNA (ctDNA) platforms were utilized to detect ALK or ROS1 gene rearrangements by FISH, or EGFR mutations, respectively.
Results: Described are three metastatic NSCLC patients for which liq.. View More»
DOI:
10.4172/2576-1447.1000113